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Abstract: Diabetes Mellitus (DM) is a common disorder affecting individuals of all ages. Similar to general 
population, diabetes mellitus (DM) can also be seen in HIV infected subjects. In this study, 150 confirmed HIV 
positive subjects, 50 of whom were on the first line drug of Lamividine, Nevirapine, Combivir, Combipack and 
efavirenze were recruited. The second group of 50 subjects was on second line drugs which consisted of 
Truvada and Aluvida. Truvada is from first line drug and comprises tenofovir and emtricitabine while aluvida is 
protease inhibitor and comprises lopinavir and ritonavir. The third group of 50 subjects was not on 
antiretroviral therapy and was used as control. All the patients were screened for diabetes mellitus (DM) before 
the commencement of antiretroviral therapy and found to be negative. Assay was performed three months after 
the commencement of therapy. There is a prevalence of 6% diabetes mellitus in those on second line drugs 
which comprised mostly protease inhibitors compared to 0% of those on the first line drug and control samples 
using a cut-point of 11.0 mmol/L of random blood sugar as recommended by World Health Organization 
(WHO). It is possible that the rise in blood glucose level may be a result of Aluvida, a protease inhibitor rather 
than Truvada a first line drug. There is also a prevalence of 10% impaired glucose intolerance based on WHO 
cut-point of 8.0mmol/l. Most of the patients recruited for this work had CD4 less than 350 cells/l, which is the 
WHO cut point before drug can be administered to a patient. Therefore primary care for HIV – infected 
individuals with reference to DM and its complication is important. 
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I. Introduction 
Diabetes mellitus is a disorder of carbohydrate metabolism in which glucose is underutilized. It is 
usually due to a combination of hereditary and environmental causes resulting in abnormally high blood sugar 
levels (hyperglycemia)1.As the disease progresses, individuals are at increased risk for the development of 
specific complications including retinopathy (which may lead to blindness), renal failure, neuropathy (nerve 
damage) and arteriosclerosis. The last condition may result in stroke, gangrene or coronary artery disease2. 
Blood glucose levels are controlled by a complex interaction of multiple chemicals and hormones in the body 
including the hormone insulin made in the beta cells of the pancreas.  
Human immunodeficiency virus (HIV) is a virus associated with disease of immune suppression with 
long incubation period after infection before manifestation of apparent illness. Infection with HIV results in 
relentless destruction of the immune system leading to onset of acquired immunodeficiency syndrome (AIDS)3,4. 
Worldwide, there were about 33 million people living with HIV as at 2007, with 2.7 million newly infected with 
the virus and 2 million HIV related deaths; 67 percent of this number were in sub-Saharan Africa and 75 percent 
of deaths from the disease were in the region too5,6. A prevalence of 4.4 percent has been reported within the 
ages of 15-49 in Nigeria with a total estimate of 2.9 million people infected with the disease5,6. Antiretroviral 
therapies (ART) are drugs that diminish HIV replication. ART is based on a cocktail of at least three 
antiretroviral agents (called highly active antiretroviral therapy (HAART) that reduce the viral load, reduce 
opportunistic infections with almost complete suppression of HIV replication7. HAART has markedly improved 
the prognosis of people with HIV infections for few years8. However, there are several clinical and metabolic 
abnormalities associated with HAART9.  
In view of this information, the present study was designed to investigate the prevalence of diabetes mellitus in 
HIV infected patients on ART. 
 
II. Methods 
SUBJECTS:  The subjects for this study comprised of 150 HIV patients grouped into (i) 50 HIV 
subjects who were on first line drugs which consisted of a combination of Nucleoside reverse transcriptase 
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inhibitors (NRTIS); non nucleoside reverse transcriptase inhibitors (NNRTIS) and nucleotide reverse 
transcriptase inhibitors (NtRTIS);these were called first line patients. (ii) 50 HIV subjects who were on the 
second line drugs which is the protease inhibitors but all the patients in this group were taking a combination of 
the first line drug and protease inhibitors mostly of Truvada and Aluvida. Truvada is a combination of Tenofovir 
and Emtricitabine while Aluvida is a combination of Lopinavir and Ritonavir these were called second line 
patients while the remaining 50 patients used as control are those not on therapy. These were called no treatment 
group.   
The criteria for the selection of a patient for this study are those that are not diabetic, or have no history of 
diabetes in their family and have no risk factors of diabetes.  
 
THE BLOOD SAMPLING/ COLLECTION:  
5ml of blood sample was collected from each of the patients. 2ml of the blood were dispensed in a 
fluoride oxalate container and the remaining 3ml of blood were dispensed into a plain bottle for HIV-1 and II 
screening. All the patients commenced ART within two weeks after testing positive for HIV. The drug doses 
were according to the natural algorithm. Glucose determination was done after three months of therapy in each 
of the study group. The patients for analysis were screened for HIV 1 and 2 using Determine, Stat-pak and Uni-
gold test kit.  
 
The Principle Of DETERMINE: 
Determine HIV - 1 AND 2 is an immuno chromatographic test for the qualitative detection of 
antibodies to HIV – 1 and 2. Sample is added to the sample pad followed by the addition of running buffer. As 
the sample migrates through the conjugate pad, it reconstitutes and mixes with the selenium colloid antigen 
conjugate. This mixture continues to migrate through the solid phase to the immobilized recombinant antigens 
and synthetic peptides at the patient’s window site. If antibodies to HIV-1 and or HIV-2 are present in the 
samples, the antibodies bind to the antigen selenium colloid at the patient window forming a red line at the 
patient’s window site. There should always be a red line at the control window10. 
 
The Principle of STAT-PAK: 
The Chembio HIV-1 and 2 stat-pak assay employs a unique combination of a specific antibody binding 
protein which is conjugated colloidal gold dye.  HIV-1 and 2 antigens are bound to the membrane solid phase. 
The sample is delivered into the sample well followed by the addition of running buffer. The buffer facilitates 
the lateral flow of the release products and promotes the binding of antibodies to the antigen; if present the 
antibodies bind to the gold conjugative antibody binding protein. In a reactive sample, the dye conjugate-
immune complex migrates on the nitrocellulose membrane and is captured by the antigens immobilize in the test 
(T) area. The sample continues to migrate along the membrane and produces a pink/purple line in the control 
area containing immunoglobulin (G) antigens11. 
 
The Principle of UNI-GOLD: 
Recombinant proteins representing immunodominant regions of the envelope proteins of HIV-1 and 2, 
glycoprotein gp41, gp120 (HIV-1) and glycoprotein gp36 (HIV-2) respectively are immobilized at the test 
region of the nitrocellulose strip. These proteins are also linked to colloidal gold and impregnated below the test 
region of the device. A narrow band of the nitrocellulose membrane is also sensitized as a control region. 
 During testing two drops of serum, plasma or whole blood is applied to the sample port, followed by two drops 
of wash buffer and allowed to react. Antibodies of any immunoglobulin class, specific to the recombinant HIV-
1 or HIV-2 proteins, will react with the colloidal gold linked antigens. The antibody colloidal gold complex 
moves chromatographically along the membrane to the test and control regions of the test device. 
 A positive reaction is visualized by a pink/red band in the test region of the device. 
 A negative reaction occurs in the absence in the absence of human immunoglobulin antibodies to HIV in the 
analyzed specimen. Consequently no visually detectable band develops in the test region of the device. 
 Excess conjugate forms a second pink/red band indicates proper performance of the reagents in the kit6.    
Glucose concentration in the blood sample was analyzed using glucose oxidase method. 
 
THE GLUCOSE OXIDASE METHOD 
 Glucose oxidase catalyses the oxidation of glucose to gluconic acid and hydrogen peroxide (H2O2) 
Glucose + H2O2 + O2                                           Gluconic acid + H2O2 
 The additional of the enzyme peroxides and a chromogenic oxygen acceptor such as o- toludine or 4 – amino 
phenazone results in the formation of a colored compound that is measured at 550nm2,12. 
 Glucose oxidase is highly specific for b – D glucose. Because 36% and 64% of glucose in solution are in the a 
and b forms respectively, complete reaction requires mutarotation of a and b forms. 
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Some commercial preparations of glucose oxidase contain an enzyme glucomutarotase that accelerates this 
reaction. Otherwise extended incubation time allows spontaneous conversion2,12. 
 
STATISTICAL ANALYSIS: The statistical analysis was performed using students t- test and a P value less 
than 0.05 (P < 0.05) was obtained indicating a significant difference between those on therapy and those not on 
therapy. 
 
III. Results 
The results showed a zero percent (0%) prevalence of diabetes mellitus on those patients on first line 
drugs. They also indicated (6%) prevalence of diabetes mellitus and 10% prevalence of impaired glucose 
tolerance in those on second line drugs.   
 
IV. Discussion 
Diabetes mellitus (DM) is a disorder of carbohydrate metabolism. It develops due to diminished 
production of insulin or resistance to its effect8.  
 The use of highly active antiretroviral therapy (HAART) has remarkably improved long-term survival 
in HIV infected subjects8. Two categories of patients were used in this study. The first category were those on 
the first line drugs i.e. Nucleoside reverse transcriptase inhibitors (NRTIS), Non-nucleoside reverse transcriptase 
inhibitors (NNRTIS) and Nucleotide i.e. protease inhibitors (PIs). While the second category are those on first 
line and second line drugs composed of protease inhibitors.   
 The study reveals 6% prevalence of Diabetes mellitus (DM) in the ART patients on the second line 
drug. The 6% prevalence rate was established using a cut- point of 11.0mmol/L according to the WHO 
recommendation of random blood sugar6. About 10% of the patients on the second line drug developed impaired 
glucose tolerance which suggests a risk of developing diabetes mellitus in future.  Yoon et al 13 reported 7% 
prevalence. Carr et al14 reported that impaired glucose intolerance occurred in 16% of protease-inhibitor 
recipients and diabetes mellitus in 7% of the 113 patients studied. They concluded that impaired glucose 
tolerance was common with these drugs. In an earlier report where diabetes developed following treatment 
protease inhibitors, the authors suggested that a familial disposition may have played a role15.   
       The knowledge of the mechanisms responsible for deterioration in glucose tolerance during protease 
inhibitor containing regimens administration is still not well understood. It is unclear whether protease inhibitors 
adversely affect pancreatic B – cell function and effect of interaction on glucose metabolism. Although protease 
inhibitors are end peptidase inhibitors and endopeptidase are involved in the conversion of proinsulin to insulin. 
The plasma proinsulin level may increase with the administration of protease inhibitors. It follows therefore that 
these drugs may directly impair pancreatic B – cell function8. It has been suggested that the hyperglycemia 
associated with protease inhibitor therapy maybe as a result of the inhibition of the protease that converts 
proinsulin to insulin16. 
 
V. Conclusion 
The use of protease inhibitor regimen may predispose HIV patients to diabetes mellitus (DM). The 
result of this study calls for attention and it is advised that HIV patients on protease inhibitors regimen be 
monitored every 3 months to screen for the development of hyperglycaemia. Blood sugar levels should be 
checked before the onset of treatment. This will identify subjects who are at greater risk, so that alternative 
drugs will be used for their treatment. Patients who have a family history of diabetes should be placed on 
alternative drugs. It is further recommended that protease inhibitors (PIS), unless absolutely necessary be 
replaced with other equally potent classes of antiretrovirals. Further studies of longer duration will be helpful in 
determining the longer term effects of these protease inhibitors.  
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